Sign In
Buy PRQR
$1.47
+0 (+0%)
At Close: Jun 03, 2026
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
07:00am, Friday, 19'th Apr 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, t
ProQR Announces Year End 2023 Operating and Financial Results
07:00am, Wednesday, 13'th Mar 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
07:00am, Friday, 19'th Jan 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
07:00am, Friday, 05'th Jan 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based
Is ProQR (PRQR) Stock a Solid Choice Right Now?
09:46am, Thursday, 28'th Dec 2023
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
07:30am, Friday, 08'th Dec 2023
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
ProQR Announces Third Quarter 2023 Operating and Financial Results
07:00am, Tuesday, 07'th Nov 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
07:00am, Monday, 06'th Nov 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, to
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
08:00am, Thursday, 28'th Sep 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
08:00am, Thursday, 07'th Sep 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR Announces Second Quarter 2023 Operating and Financial Results
07:00am, Thursday, 03'rd Aug 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets
07:00am, Tuesday, 01'st Aug 2023
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
ProQR: Too Many Failures For Its RNA Technology
06:53am, Sunday, 09'th Jul 2023
PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here.
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
07:00am, Thursday, 06'th Jul 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
09:53am, Tuesday, 16'th May 2023
ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a year ago.
